Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab

  1. Motzer, R.
  2. George, S.
  3. Merchan, J.R.
  4. Hutson, T.E.
  5. Song, X.
  6. Perini, R.F.
  7. Xie, R.
  8. Bapat, U.
  9. Puente, J.

ISSN: 1549-490X 1083-7159

Year of publication: 2023

Volume: 28

Issue: 6

Pages: 501-509

Type: Article

DOI: 10.1093/ONCOLO/OYAC269 GOOGLE SCHOLAR lock_openOpen access editor